UNSPSC 51151659: Pipenzolate

This classification denotes a piperidine with the molecular formula C22H28NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RS3K5YXV34, chemically known as 1-ethyl-3-hydroxy-1-methyl-piperidinium bromide, benzilic acid ester but generally known as pipenzolate, which bears US NIH Compound Identifier 4832. European Medicines Agency schedules Pipenzolate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03838MIG.

World Health Organization schedules pipenzolate in its Anatomical Therapeutic Chemical (ATC) Classification. PIPENZOLATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, PIPENZOLATE remains the US FDA Preferred Term for this commodity. SMILES: O(C1C[N](CCC1)(CC)C)C(=O)C(O)(C1CCCCC1)C1CCCCC1.

UNSPSC 51151659 Pipenzolate is a Commodity code that in recent state and local procurement reflects a significant mismatch between the code's nominal pharmaceutical scope and the actual work being solicited. The two opportunities tagged under this code involve naloxone procurement and prescription-fulfillment program design, neither of which aligns with pipenzolate—an anticholinergic agent—as a procurement focus. Seminole County, Florida is soliciting naloxone and drug deactivation systems through competitive bidding, while the Texas Health and Human Services Commission has issued a Request for Information to assess vendor capability for a direct-to-manufacturer prescription program. The issuing bodies represent county health authorities and state HHS agencies, but the opportunities themselves do not substantiate pipenzolate as an active procurement category in state and local markets.

Recent activity is concentrated in Florida and Texas. Seminole County's IFB 60459723LAS, posted June 30, 2026, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to the Seminole County Community Health Building in Sanford, Florida; response deadline was July 26, 2023. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, addresses pharmacy benefit program design rather than specific pharmaceutical commodity procurement. The code shows little relevant recent activity aligned with pipenzolate itself; business development professionals should treat this as a low-signal category and confirm with issuing agencies whether pipenzolate represents actual procurement intent or a miscoded opportunity.